BACKGROUND: The germline CHEK2*1100delC variant has been associated with breast cancer in multiple case families where involvement of BRCA1 and BRCA2 has been excluded. METHODS: We have investigated the tumour characteristics and prognosis of carriers of this germline variant by means of a prospective cohort study in an unselected cohort of 1084 consecutive patients with primary breast cancer. Data were collected for 34 patients with a germline CHEK2*1100delC mutation and for 102 patients without this mutation, stratified by age and date of diagnosis of the first primary breast cancer (within 1 year). RESULTS: Carriers developed steroid receptor positive tumours (oestrogen receptor (ER): 91%; progesterone receptor (PR): 81%) more frequently than non-carriers (ER: 69%; PR: 53%; p = 0.04). Mutation carriers more frequently had a female first or second degree relative with breast cancer (p = 0.03), or had any first or second degree relative with breast or ovarian cancer (p = 0.04). Patients with the CHEK2 variant had a more unfavourable prognosis regarding the occurrence of contralateral breast cancer (relative risk (RR) = 5.74; 95% confidence interval (CI) 1.67 to 19.65), distant metastasis-free survival (RR = 2.81; 95% CI 1.20 to 6.58), and disease-free survival (RR = 3.86; 95% CI 1.91 to 7.78). As yet, no difference with respect to overall survival has been found at a median follow up of 3.8 years. CONCLUSION: We conclude that carrying the CHEK2*1100delC mutation is an adverse prognostic indicator for breast cancer. If independently confirmed by others, intensive surveillance, and possibly preventive measures, should be considered for newly diagnosed breast cancer cases carrying the CHEK2*1100delC variant.
BACKGROUND: The germline CHEK2*1100delC variant has been associated with breast cancer in multiple case families where involvement of BRCA1 and BRCA2 has been excluded. METHODS: We have investigated the tumour characteristics and prognosis of carriers of this germline variant by means of a prospective cohort study in an unselected cohort of 1084 consecutive patients with primary breast cancer. Data were collected for 34 patients with a germline CHEK2*1100delC mutation and for 102 patients without this mutation, stratified by age and date of diagnosis of the first primary breast cancer (within 1 year). RESULTS: Carriers developed steroid receptor positive tumours (oestrogen receptor (ER): 91%; progesterone receptor (PR): 81%) more frequently than non-carriers (ER: 69%; PR: 53%; p = 0.04). Mutation carriers more frequently had a female first or second degree relative with breast cancer (p = 0.03), or had any first or second degree relative with breast or ovarian cancer (p = 0.04). Patients with the CHEK2 variant had a more unfavourable prognosis regarding the occurrence of contralateral breast cancer (relative risk (RR) = 5.74; 95% confidence interval (CI) 1.67 to 19.65), distant metastasis-free survival (RR = 2.81; 95% CI 1.20 to 6.58), and disease-free survival (RR = 3.86; 95% CI 1.91 to 7.78). As yet, no difference with respect to overall survival has been found at a median follow up of 3.8 years. CONCLUSION: We conclude that carrying the CHEK2*1100delC mutation is an adverse prognostic indicator for breast cancer. If independently confirmed by others, intensive surveillance, and possibly preventive measures, should be considered for newly diagnosed breast cancer cases carrying the CHEK2*1100delC variant.
Authors: B Chevallier; F Heintzmann; V Mosseri; J P Dauce; P Bastit; Y Graic; P Brunelle; J P Basuyau; M Comoz; B Asselain Journal: Cancer Date: 1988-12-15 Impact factor: 6.860
Authors: S R Lakhani; J Jacquemier; J P Sloane; B A Gusterson; T J Anderson; M J van de Vijver; L M Farid; D Venter; A Antoniou; A Storfer-Isser; E Smyth; C M Steel; N Haites; R J Scott; D Goldgar; S Neuhausen; P A Daly; W Ormiston; R McManus; S Scherneck; B A Ponder; D Ford; J Peto; D Stoppa-Lyonnet; Y J Bignon; J P Struewing; N K Spurr; D T Bishop; J G Klijn; P Devilee; C J Cornelisse; C Lasset; G Lenoir; R B Barkardottir; V Egilsson; U Hamann; J Chang-Claude; H Sobol; B Weber; M R Stratton; D F Easton Journal: J Natl Cancer Inst Date: 1998-08-05 Impact factor: 13.506
Authors: Hanne Meijers-Heijboer; Juul Wijnen; Hans Vasen; Marijke Wasielewski; Anja Wagner; Antoinette Hollestelle; Fons Elstrodt; Renate van den Bos; Anja de Snoo; Grace Tjon A Fat; Cecile Brekelmans; Shantie Jagmohan; Patrick Franken; Paul Verkuijlen; Ans van den Ouweland; Pamela Chapman; Carli Tops; Gabriela Möslein; John Burn; Henry Lynch; Jan Klijn; Riccardo Fodde; Mieke Schutte Journal: Am J Hum Genet Date: 2003-04-10 Impact factor: 11.025
Authors: L C Verhoog; C T Brekelmans; C Seynaeve; L M van den Bosch; G Dahmen; A N van Geel; M M Tilanus-Linthorst; C C Bartels; A Wagner; A van den Ouweland; P Devilee; E J Meijers-Heijboer; J G Klijn Journal: Lancet Date: 1998-01-31 Impact factor: 79.321
Authors: Petra E A Huijts; Antoinette Hollestelle; Brunilda Balliu; Jeanine J Houwing-Duistermaat; Caro M Meijers; Jannet C Blom; Bahar Ozturk; Elly M M Krol-Warmerdam; Juul Wijnen; Els M J J Berns; John W M Martens; Caroline Seynaeve; Lambertus A Kiemeney; Henricus F van der Heijden; Rob A E M Tollenaar; Peter Devilee; Christi J van Asperen Journal: Eur J Hum Genet Date: 2013-05-08 Impact factor: 4.246
Authors: Marijke C Jansen-van der Weide; Marcel J W Greuter; Liesbeth Jansen; Jan C Oosterwijk; Ruud M Pijnappel; Geertruida H de Bock Journal: Eur Radiol Date: 2010-06-27 Impact factor: 5.315
Authors: Daphne W Bell; Sang H Kim; Andrew K Godwin; Taryn A Schiripo; Patricia L Harris; Sara M Haserlat; Doke C R Wahrer; Christopher A Haiman; Mary B Daly; Kristin B Niendorf; Matthew R Smith; Dennis C Sgroi; Judy E Garber; Olufunmilayo I Olopade; Loic Le Marchand; Brian E Henderson; David Altshuler; Daniel A Haber; Matthew L Freedman Journal: Int J Cancer Date: 2007-12-15 Impact factor: 7.396
Authors: Stephanie L Greville-Heygate; Tom Maishman; William J Tapper; Ramsey I Cutress; Ellen Copson; Alison M Dunning; Linda Haywood; Louise J Jones; Diana M Eccles Journal: JCO Precis Oncol Date: 2020-05-04
Authors: El Mustapha Bahassi; Susan B Robbins; Moying Yin; Gregory P Boivin; Raoul Kuiper; Harry van Steeg; Peter J Stambrook Journal: Proc Natl Acad Sci U S A Date: 2009-09-21 Impact factor: 11.205
Authors: Diether Lambrechts; Therese Truong; Christina Justenhoven; Manjeet K Humphreys; Jean Wang; John L Hopper; Gillian S Dite; Carmel Apicella; Melissa C Southey; Marjanka K Schmidt; Annegien Broeks; Sten Cornelissen; Richard van Hien; Elinor Sawyer; Ian Tomlinson; Michael Kerin; Nicola Miller; Roger L Milne; M Pilar Zamora; José Ignacio Arias Pérez; Javier Benítez; Ute Hamann; Yon-Dschun Ko; Thomas Brüning; Jenny Chang-Claude; Ursel Eilber; Rebecca Hein; Stefan Nickels; Dieter Flesch-Janys; Shan Wang-Gohrke; Esther M John; Alexander Miron; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Georgia Chenevix-Trench; Jonathan Beesley; Xiaoqing Chen; Florence Menegaux; Emilie Cordina-Duverger; Chen-Yang Shen; Jyh-Cherng Yu; Pei-Ei Wu; Ming-Feng Hou; Irene L Andrulis; Teresa Selander; Gord Glendon; Anna Marie Mulligan; Hoda Anton-Culver; Argyrios Ziogas; Kenneth R Muir; Artitaya Lophatananon; Suthee Rattanamongkongul; Puttisak Puttawibul; Michael Jones; Nicholas Orr; Alan Ashworth; Anthony Swerdlow; Gianluca Severi; Laura Baglietto; Graham Giles; Melissa Southey; Federik Marmé; Andreas Schneeweiss; Christof Sohn; Barbara Burwinkel; Betul T Yesilyurt; Patrick Neven; Robert Paridaens; Hans Wildiers; Hermann Brenner; Heiko Müller; Volker Arndt; Christa Stegmaier; Alfons Meindl; Sarah Schott; Claus R Bartram; Rita K Schmutzler; Angela Cox; Ian W Brock; Graeme Elliott; Simon S Cross; Peter A Fasching; Ruediger Schulz-Wendtland; Arif B Ekici; Matthias W Beckmann; Olivia Fletcher; Nichola Johnson; Isabel Dos Santos Silva; Julian Peto; Heli Nevanlinna; Taru A Muranen; Kristiina Aittomäki; Carl Blomqvist; Thilo Dörk; Peter Schürmann; Michael Bremer; Peter Hillemanns; Natalia V Bogdanova; Natalia N Antonenkova; Yuri I Rogov; Johann H Karstens; Elza Khusnutdinova; Marina Bermisheva; Darya Prokofieva; Shamil Gancev; Anna Jakubowska; Jan Lubinski; Katarzyna Jaworska; Katarzyna Durda; Børge G Nordestgaard; Stig E Bojesen; Charlotte Lanng; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Paolo Radice; Paolo Peterlongo; Siranoush Manoukian; Loris Bernard; Fergus J Couch; Janet E Olson; Xianshu Wang; Zachary Fredericksen; Grethe Grenaker Alnaes; Vessela Kristensen; Anne-Lise Børresen-Dale; Peter Devilee; Robert A E M Tollenaar; Caroline M Seynaeve; Maartje J Hooning; Montserrat García-Closas; Stephen J Chanock; Jolanta Lissowska; Mark E Sherman; Per Hall; Jianjun Liu; Kamila Czene; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Annika Lindblom; Sara Margolin; Alison M Dunning; Paul D P Pharoah; Douglas F Easton; Pascal Guénel; Hiltrud Brauch Journal: Hum Mutat Date: 2012-04-30 Impact factor: 4.878